ArticleCureus2026
A Retrospective Analysis of ADAMTS13 Enzymatic Activity Results in a Population With Thrombotic Thrombocytopenic Purpura Disease in the Arabian Gulf and Colombia (APOLO Study).
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little is known about the thrombospondin type-1 motif, member 13 (ADAMTS-13) enzymatic activity in subjects with suspected/confirmed thrombotic thrombocytopenic purpura (TTP) in the Arabian Gulf and Colombia. The retrospective analysis of ADAMTS13 enzymatic activity results in a population with thrombotic thrombocytopenic purpura disease in the Arabian Gulf and Colombia (APOLO study) aimed to report on ADAMTS-13 enzymatic activity, subject demographics, and the turnaround time for results. This study used laboratory analyses of ADAMTS-13 enzymatic activity in blood samples from subjects with suspected/confirmed TTP in the Arabian Gulf (N=235) and in Colombia (N=155). The primary objective was to report ADAMTS-13 enzymatic activity levels and distribution in categories: severe deficiency <10% (TTP diagnosis), borderline activity 10-20%, and no deficiency >20%. Descriptive statistics were performed using SAS 9.4 (SAS Institute Inc., North Carolina, USA). Among the 390 samples, the average ADAMTS-13 activity level was 42.8%±31.1. Severe deficiency (ADAMTS-13 activity <10%, 1.7%±1.9, indicative of TTP) was found in 91 samples (23.3%) and borderline ADAMTS-13 activity (15.4%±3.0) in 17 (4.4%) samples. The median age among subjects with TTP was 39 years. The average turnaround time for results was 4.4±5.9 days, with a median of 2.0 days. The average turnaround time was significantly longer for samples from the Arabian Gulf (6.5±6.9 days) compared to those from Colombia (1.2±0.8 days, Wilcoxon/Mann-Whitney W-value=18507.5, P<0.001). In conclusion, the median age of subjects with TTP in this study matched the age reported in the literature. The turnaround time is a global concern, as it can lead to delayed confirmatory results and potentially life-saving treatment. In Colombia, the turnaround time considerably benefits TTP management, underscoring the necessity to determine reasons behind occasional result turnaround delays in the Arabian Gulf.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.